©2015 MFMER | 3428638-1 Robotic Repair of Simple vs. Complex Degenerative Mitral Valve Disease Clinical and Echocardiographic Outcomes During Mid-Term.

Slides:

Advertisements

Similar presentations

Underwriting Impact of New Advances in Valvular Heart Disease NEHOUA 2012 Michael Clark, FACC, FLMI, FBIM Chief Medical Director Swiss Re.

Advertisements

Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The.

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

Fate of Un-replaced Sinuses of Valsalva in Bicuspid Aortic Valve Disease: Follow-up to 17 years Chan Park 1, Hector Michelena 2, Thoralf M. Sundt 1 Divisions.

Percutaneous mitral valve repair using the MitraClip® device (e-valve)

SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.

Khalil Fattouch, Roberta Sampognaro, Giuseppe Speziale, Marco Caruso, Pietro Dioguardi, Salvatore Novo, Giovanni Ruvolo. Disclosures: None Disclosures:

STICH Mitral Regurgitation Subanalysis Objective Examine the relationship of mitral regurgitation (MR) severity and survival and compare outcomes in patients.

Following the Outpatient with Severe Mitral Regurgitation Marilyn Weigner MD RIACC 9/02.

University Heart Center Hamburg

Ultra long term outcomes in adult survivors of tetralogy of Fallot and the effect of pulmonary valve replacement Dobson R1,2, Danton M2, Walker N2, Tzemos,

Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.

Long terms results after bicuspid aortic valve repair according to functional classification of aortic insufficiency Khalil Fattouch, Giacomo Murana, Sebastiano.

The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis Following Myocardial Infarction: The VALIANT Echo Study Anil Verma,

Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:

Mitral Valve Surgery: Lessons from New York State Joanna Chikwe, MD Professor of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai Chairman.

A 20-year Experience with Isolated Pericardiectomy An Analysis of Indications and Outcomes Gillaspie EA, Stulak JM, Daly RC, Greason KL, Joyce LD, Oh J,

Department of Surgery, University of Pennsylvania Health System Which Operation is Best for Severe Ischemic MR: Repair or Replace? Michael Acker William.

Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

A Contemporary Analysis of Pulmonary Hypertension in Patients Undergoing Mitral Valve Surgery: Is this a Risk Factor? Thank you to the society and panel.

Ryan Hampton OMS IV January  Considerations Is MR severe? Is patient symptomatic? Is patient a good candidate? What is Left Ventricular function?

Intra-ventricular Papillary Muscle Head Approximation is Effective in Treating Ischemic MR in Dilated Ventricles - Comparison with Ring annuloplasty Muralidhar.

EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.

+ Mitral Valve Prolapse A Surgeon’s Perspective Charles Anderson, M.D. Saint Joseph’s Hospital of Atlanta.

Asymptomatic mitral regurgitation When should you operate? Ben Bridgewater Cardiac surgeon and lead clinician, UHSM, Manchester Honorary Reader, Manchester.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

The Place of Closed Mitral Valvotomy Procedure in Facility Deprived Countries in the Modern PTMC/PMBV Era: 20 Years Experience at SMS Hospital, Jaipur,

Primary Mitral Regurgitation Degenerative Mitral Valve Disease

The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Transcatheter Aortic Valve Replacement Andres M. Pineda MD, J. Kevin.

Current Surgical Standards for Mitral Leaflet and Chordal Repair: Patient Selection,Techniques and Clinical Outcomes CRT February 2011 Niv Ad, MD Chief,

Role of Device Therapy in FMR: Challenges and Opportunities

Minimally Invasive Mitral Valve Repair

Highlights From the SAPIEN 3 Experience in Intermediate-Risk Patients Vinod H. Thourani, MD on behalf of the PARTNER Trial Investigators Professor.

Division of Cardiac Surgery University of Ottawa Heart Institute

University of Pennsylvania Philadelphia

Functional MR: When to Intervene

A report from the STS/ACC TVT Registry

Washington Hospital Center

Thierry MESANA, MD, PhD President and CEO Professor Cardiac Surgery

Surgical Mitral Valve Repair: What is the Gold Standard?

EVEREST II 5-Year Report and Beyond

University Heart Center Hamburg

Degenerative Mitral Stenosis Unmet Need for Percutaneous Interventions

Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry

Cardiovacular Research Technologies

Nishith Patel Waikato Cardiothoracic Unit

Left ventricular dysfunction after mitral valve repair—the fallacy of “normal” preoperative myocardial function Eduard Quintana, MD, Rakesh M. Suri,

Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators

Very long-term durability of the edge-to-edge repair for isolated anterior mitral leaflet prolapse: Up to 21 years of clinical and echocardiographic results

Mild-to-moderate functional tricuspid regurgitation in patients undergoing mitral valve surgery Sun Kyun Ro, MD, Joon Bum Kim, MD, Sung Ho Jung, MD,

Is there an outcome penalty linked to guideline-based indications for valvular surgery? Early and long-term analysis of patients with organic mitral regurgitation

Surgical Repair of Posterior Mitral Valve Prolapse: Implications for Guidelines and Percutaneous Repair Douglas R. Johnston, MD, A. Marc Gillinov, MD,

Benefits of Early Surgery on Clinical Outcomes After Degenerative Mitral Valve Repair Tianyu Zhou, MD, Jun Li, MD, PhD, Hao Lai, MD, PhD, Kai Zhu, MD,

Impact of Left Ventricular Systolic Function on Outcome of Correction of Chronic Severe Aortic Valve Regurgitation: Implications for Timing of Surgical.

Clinical and echocardiographic outcomes after repair of mitral valve bileaflet prolapse due to myxomatous disease Vincent Chan, MD, MPH, Marc Ruel, MD,

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.

Simple versus complex degenerative mitral valve disease

Michael A. Borger, MD, PhD, Patricia M

Vikas Sharma, MBBS, Rakesh M. Suri, MD, DPhil, Joseph A

Left ventricular dysfunction after degenerative mitral valve repair: A question of better molecular targets or better surgical timing? Jordan D. Miller,

John M. Stulak, MD, Rakesh M. Suri, MD, DPhil, Joseph A

Morgan L. Brown, MD, Hartzell V. Schaff, MD, Zhuo Li, MS, Rakesh M

Robotic mitral valve repair for all prolapse subsets using techniques identical to open valvuloplasty: Establishing the benchmark against which percutaneous.

Survival Advantage and Improved Durability of Mitral Repair for Leaflet Prolapse Subsets in the Current Era Rakesh M. Suri, MD, DPhil, Hartzell V. Schaff,

Rick A. Nishimura et al. JACC 2017;70:

Recovery of left ventricular function after surgical correction of mitral regurgitation caused by leaflet prolapse Rakesh M. Suri, MD, DPhil, Hartzell.

Chordal replacement with polytetrafluoroethylene sutures for mitral valve repair: A 25- year experience Tirone E. David, MD, Susan Armstrong, MSc, Joan.

Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.

Presentation transcript:

©2015 MFMER | Robotic Repair of Simple vs. Complex Degenerative Mitral Valve Disease Clinical and Echocardiographic Outcomes During Mid-Term Follow-up RM Suri, A Taggarse, H Burkhart, R Daly, W Mauermann, H Michelena, Z Li, R Nishimura, M Enriquez-Sarano Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota

©2015 MFMER | Disclosure Mayo Clinic Division of Cardiovascular Surgery Research funding Edwards Lifesciences St. Jude Medical Sorin Group Current technology licensing agreements Sorin Group and St. Jude Principle Investigator FDA Perceval Trial – Sorin Group Co-Investigator PARTNER II, COAPT, SURTAVI, PORTICO No personal relationships with Industry

©2015 MFMER | A.At risk B.Progressive C.Asymptomatic severe C1: Asymptomatic – ventricle compensated C2: Asymptomatic – decompensated ventricle D.Symptomatic severe 2014 ACC/AHA Guideline Summary Stages of Progression of VHD Unknown mid-term outcomes Complex disease Minimally invasive approaches Unknown mid-term outcomes Complex disease Minimally invasive approaches When leaflet dysfunction is sufficiently limited so that only annuloplasty and repair of the posterior leaflet are necessary… superior outcomes … 80% freedom from recurrent moderate/severe (≥3+) MR 20 years after operation.

©2015 MFMER | Hypothesis In patients undergoing robotic correction of severe primary degenerative MR, overall survival, rate of recurrence of mitral regurgitation and mitral reoperation are influenced by repair complexity.

©2015 MFMER | Inclusion and Methods Jan – Jan. 2015: 520 pt. robotic mitral valve repair for primary degenerative disease Study consent 487 pt. – analysis Stratified simple vs. complex disease Two surgeon approach: HMB / RMS 85% RCD / RMS 15% Procolized follow up Data collection

©2015 MFMER |

©2015 MFMER | Posterior 57.9% Bileaflet 39.0% Anterior 2.9% Traditional Stratification Prolapse Categories

©2015 MFMER | New Classification – Complexity Intervention Categories Simple 59% Complex 41% Repair rate – 100% 1 Death – 0.2% 4 Neurologic events – 0.8%

©2015 MFMER | Patient Characteristics Total (n=487) Simple (n=289) Complex (n=198)P NYHA III/IV25 (5.1)13 (4.5)12 (6.1)0.443 Congestive heart failure12 (2.5)7 (2.4)5 (2.5)0.943 Atrial fibrillation43 (8.8)23 (8.0)20 (10.1)0.413 Ejection fraction, mean (SD)64.8 (6.3)64.9 (6.4)64.6 (6.1) LVEDD, mm, mean (SD)58.0 (5.3)57.8 (5.3)58.4 (5.4) LVESD, mm, mean (SD)35.6 (4.3)35.5 (4.3)35.6 (4.4) LAVI, mL/m 2, mean (SD)56.3 (18.0)55.4 (18.4)57.6 (17.4) Age, years, mean (SD)55.6 (11.0)56.7 (10.1)53.9 (12.1)0.005 Male sex360 (73.9)235 (81.3)12 (63.1)<0.001 Regurgitant volume, mL, median (IQR) 76 (63-96)79 (64-102)73 (61-90) 0.009

©2015 MFMER | Total (n=487) Simple (n=289) Complex (n=198)P Plication39 (8.0)11 (3.8)28 (14.1)<0.001 Gore-Tex Neochord111 (22.6)3 (1.0)107 (54.0)< Annuloplasty487 (100.0)287 (100.0)200 (100.0)>0.99 Cryoablation maze 29 (5.9)16 (5.5)13 (6.6) Left atrial appendage ligation29 (5.9)17 (5.7)12 (6.1) Post-op ICU stay, hrs, median (IQR)8 ( )8 ( )8 ( ) Blood bank RBC requirement, median (IQR) 0 (0-0) MR grade at dismissal None to trivial436 (89.7)259 (89.6)177 (89.8) Mild50 (10.3)30 (10.4)20 (10.2) Procedure and Early Outcomes Leaflet resection430 (88.3)276 (95.5)154 (77.8)<0.001 Commissuroplasty any148 (30.4)43 (15.0)105 (52.5)<0.001 X-clamp time, min, median (IQR)53 (45-66)50 (42-62)58 (49-72)<0.001 Post-op ventilation, hrs, median (IQR)0 (0-0) Perfusion time, min, median (IQR)76 (66-94)74 (64-91)81 (70-98) % Complete follow-up

©2015 MFMER | Overall Survival Repair Complexity % P = Complexity Simple repair Complex repair Follow-up time (year) 99.5%

©2015 MFMER | Probability Mitral Regurgitation Recurrence Repair Complexity Recurrence ≥Moderate MR % Follow-up time (year) Complexity Simple repair Complex repair P = % 5.4%

©2015 MFMER | X-Clamp Time (per 15 min) Regurgitation Volume  90 Prolapse: Anterior & Posterior Prolapse: Anterior Plication Myxo Disease: Yes LVESD preop  40 LVEDD preop  60 Leaflet Resection Gore-Tex Neochord Gender: Male EF Preop:  60 Complex Comissuroplasty: Any Age  70 Predictors Mitral Regurgitation Recurrence Univariate Hazard ratio *

©2015 MFMER | Probability Mitral Re-operation Repair Complexity Follow-up time (year) Complexity Simple repair Complex repair P = % 2.3% Mitral Reoperation %

©2015 MFMER | X-Clamp Time (per 15 min) Regurgitation Volume  90 Prolapse: Anterior & Posterior Prolapse: Anterior Plication Myxo Disease: Yes LVESD preop  40 LVEDD preop  60 Leaflet Resection Gore-Tex Neochord Gender: Male EF Preop:  60 Complex Comissuroplasty: Any Age  70 Mitral Reoperation Univariate Hazard ratio * *

©2015 MFMER | Conclusions First mid-term clinical and echocardiographic stratify - repair complexity 100% repair, 0.2% mortality, 0.8% neurologic Simple vs. complex - similar mid-term survival, freedom from MR and reoperation Univariate anterior prolapse may be associated with: MR recurrence Reoperation Robotic mitral repair High quality alternative to traditional approaches Relevant comparator percutaneous technology

©2015 MFMER | Division of Cardiovascular Surgery